---
document_datetime: 2025-12-02 05:02:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tecvayli.html
document_name: tecvayli.html
version: success
processing_time: 0.1353119
conversion_datetime: 2025-12-28 12:17:01.41269
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tecvayli

[RSS](/en/individual-human-medicine.xml/67605)

##### Authorised

This medicine is authorised for use in the European Union

teclistamab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tecvayli](#news-on)
- [More information on Tecvayli](#more-information-on-tecvayli-953)
- [More information on Tecvayli](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tecvayli is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow). It can be used in patients who have received at least three previous treatments for their cancer, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.

Tecvayli contains the active substance teclistamab.

Expand section

Collapse section

## How is Tecvayli used?

The medicine can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the management of multiple myeloma, in a location with appropriate medical support to manage severe side effects such as cytokine release syndrome (a potentially life-threatening condition that causes fever, vomiting, shortness of breath, headache and low blood-pressure; see risks section below).

Tecvayli is given as an injection under the skin. The recommended dose is based on the patient's body weight. Treatment starts with injections on days 1, 3 and 5 at increasing doses (so-called step-up dosing). One to three hours before receiving these injections, patients are given medicines to reduce the risk of developing cytokine release syndrome. After step-up dosing, patients are given maintenance doses once a week. Treatment can continue until the disease gets worse or the patient experiences unacceptable side effects.

For more information about using Tecvayli, see the package leaflet or contact your doctor or pharmacist.

## How does Tecvayli work?

The active substance in Tecvayli is teclistamab, an antibody (a type of protein) that is designed to recognise and attach to two targets simultaneously: the B cell maturation antigen (BCMA) on myeloma cells and CD3 on the surface of T cells (cells in the immune system). By attaching to these target proteins, this medicine brings the cancer cells and T cells together. This activates the T cells, which then kill the multiple myeloma cells.

## What benefits of Tecvayli have been shown in studies?

The benefits of Tecvayli have been investigated in an ongoing study involving 165 patients with multiple myeloma who had received at least three prior treatments (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and whose disease had not improved (refractory) or had come back (relapsed) after the last treatment. The study did not compare Tecvayli with other medicines or placebo (a dummy treatment). In this study, 63% (104 out of 165) of patients responded to treatment with Tecvayli and they lived for an average of 18 months without their disease getting worse.

## What are the risks associated with Tecvayli?

The most common side effects with Tecvayli (which may affect more than 1 in 10 people) are hypogammaglobulinaemia (low immunoglobulin or antibody levels in the blood, which increases the risk of infection), cytokine release syndrome, neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), anaemia (low levels of red blood cells or haemoglobin), pain in the muscles and bones, tiredness, thrombocytopenia (low levels of blood platelets, components that help the blood to clot), injection site reactions, upper respiratory tract (nose and throat) infection, lymphopenia (low levels of lymphocytes, a type of white blood cell), diarrhoea, pneumonia (infection of the lungs), nausea (feeling sick), fever, headache, cough, constipation and pain.

The most common serious side effects are pneumonia, COVID-19, cytokine release syndrome, sepsis (blood poisoning; when bacteria and their toxins circulate in the blood, leading to organ damage), fever, pain in the muscles and bones, acute kidney injury, diarrhoea, cellulitis (inflammation of deep skin tissue), hypoxia (lack of oxygen in body tissues), febrile neutropenia (low levels of neutrophils with fever), and encephalopathy (a brain disorder).

For the full list of side effects and restrictions of Tecvayli, see the package leaflet.

## Why is Tecvayli authorised in the EU?

At the time of approval, treatment options were limited for patients with multiple myeloma once they no longer respond to an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. Tecvayli addressed a medical need in these patients and showed a clinically relevant treatment effect, although the lack of a comparator, the short duration of the follow?up of patients within the main study and the small number of patients involved in this study limited the evaluation of the benefits and risks associated with its use.

Tecvayli has therefore been given 'conditional authorisation'. This means that that the European Medicines Agency decided that the benefits of Tecvayli are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the European Medicines Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

## What information is still awaited for Tecvayli?

Since Tecvayli has been given conditional authorisation, the company that markets this medicine is required to submit the final results of the ongoing study in patients with multiple myeloma who were treated with Tecvayli. In addition, they will have to provide data from a study that compares the effectiveness of Tecvayli in combination with daratumumab (another cancer medicine) with that of other treatments currently authorised for use in adults with relapsed or refractory multiple myeloma.

## What measures are being taken to ensure the safe and effective use of Tecvayli?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecvayli have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tecvayli are continuously monitored. Suspected side effects reported with Tecvayli are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tecvayli

Tecvayli received a conditional marketing authorisation valid throughout the EU on 23 August 2022.

Tecvayli : EPAR - Medicine Overview

Reference Number: EMA/788391/2022

English (EN) (115.49 KB - PDF)

**First published:** 13/10/2022

[View](/en/documents/overview/tecvayli-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-793)

български (BG) (142.78 KB - PDF)

**First published:**

13/10/2022

[View](/bg/documents/overview/tecvayli-epar-medicine-overview_bg.pdf)

español (ES) (118.28 KB - PDF)

**First published:**

13/10/2022

[View](/es/documents/overview/tecvayli-epar-medicine-overview_es.pdf)

čeština (CS) (140.65 KB - PDF)

**First published:**

13/10/2022

[View](/cs/documents/overview/tecvayli-epar-medicine-overview_cs.pdf)

dansk (DA) (115.75 KB - PDF)

**First published:**

13/10/2022

[View](/da/documents/overview/tecvayli-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.24 KB - PDF)

**First published:**

13/10/2022

[View](/de/documents/overview/tecvayli-epar-medicine-overview_de.pdf)

eesti keel (ET) (114.61 KB - PDF)

**First published:**

13/10/2022

[View](/et/documents/overview/tecvayli-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.36 KB - PDF)

**First published:**

13/10/2022

[View](/el/documents/overview/tecvayli-epar-medicine-overview_el.pdf)

français (FR) (118.86 KB - PDF)

**First published:**

13/10/2022

[View](/fr/documents/overview/tecvayli-epar-medicine-overview_fr.pdf)

hrvatski (HR) (149.61 KB - PDF)

**First published:**

13/10/2022

[View](/hr/documents/overview/tecvayli-epar-medicine-overview_hr.pdf)

italiano (IT) (115.92 KB - PDF)

**First published:**

13/10/2022

[View](/it/documents/overview/tecvayli-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (156.91 KB - PDF)

**First published:**

13/10/2022

[View](/lv/documents/overview/tecvayli-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.16 KB - PDF)

**First published:**

13/10/2022

[View](/lt/documents/overview/tecvayli-epar-medicine-overview_lt.pdf)

magyar (HU) (139.98 KB - PDF)

**First published:**

13/10/2022

[View](/hu/documents/overview/tecvayli-epar-medicine-overview_hu.pdf)

Malti (MT) (152.07 KB - PDF)

**First published:**

13/10/2022

[View](/mt/documents/overview/tecvayli-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.5 KB - PDF)

**First published:**

13/10/2022

[View](/nl/documents/overview/tecvayli-epar-medicine-overview_nl.pdf)

polski (PL) (143.26 KB - PDF)

**First published:**

13/10/2022

[View](/pl/documents/overview/tecvayli-epar-medicine-overview_pl.pdf)

português (PT) (118.87 KB - PDF)

**First published:**

13/10/2022

[View](/pt/documents/overview/tecvayli-epar-medicine-overview_pt.pdf)

română (RO) (138.75 KB - PDF)

**First published:**

13/10/2022

[View](/ro/documents/overview/tecvayli-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.32 KB - PDF)

**First published:**

13/10/2022

[View](/sk/documents/overview/tecvayli-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.91 KB - PDF)

**First published:**

13/10/2022

[View](/sl/documents/overview/tecvayli-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.62 KB - PDF)

**First published:**

13/10/2022

[View](/fi/documents/overview/tecvayli-epar-medicine-overview_fi.pdf)

svenska (SV) (115.75 KB - PDF)

**First published:**

13/10/2022

[View](/sv/documents/overview/tecvayli-epar-medicine-overview_sv.pdf)

Tecvayli : EPAR - Risk management plan

English (EN) (370.59 KB - PDF)

**First published:** 13/10/2022

**Last updated:** 04/06/2025

[View](/en/documents/rmp/tecvayli-epar-risk-management-plan_en.pdf)

## Product information

Tecvayli : EPAR - Product Information

English (EN) (291.65 KB - PDF)

**First published:** 13/10/2022

**Last updated:** 08/10/2025

[View](/en/documents/product-information/tecvayli-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-132)

български (BG) (321.03 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/bg/documents/product-information/tecvayli-epar-product-information_bg.pdf)

español (ES) (319.49 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/es/documents/product-information/tecvayli-epar-product-information_es.pdf)

čeština (CS) (340.32 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/cs/documents/product-information/tecvayli-epar-product-information_cs.pdf)

dansk (DA) (313.26 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/da/documents/product-information/tecvayli-epar-product-information_da.pdf)

Deutsch (DE) (336.74 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/de/documents/product-information/tecvayli-epar-product-information_de.pdf)

eesti keel (ET) (333.84 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/et/documents/product-information/tecvayli-epar-product-information_et.pdf)

ελληνικά (EL) (329.97 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/el/documents/product-information/tecvayli-epar-product-information_el.pdf)

français (FR) (311.54 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/fr/documents/product-information/tecvayli-epar-product-information_fr.pdf)

hrvatski (HR) (322.74 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/hr/documents/product-information/tecvayli-epar-product-information_hr.pdf)

íslenska (IS) (336.04 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/is/documents/product-information/tecvayli-epar-product-information_is.pdf)

italiano (IT) (303.52 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/it/documents/product-information/tecvayli-epar-product-information_it.pdf)

latviešu valoda (LV) (322.33 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/lv/documents/product-information/tecvayli-epar-product-information_lv.pdf)

lietuvių kalba (LT) (333.42 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/lt/documents/product-information/tecvayli-epar-product-information_lt.pdf)

magyar (HU) (335.36 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/hu/documents/product-information/tecvayli-epar-product-information_hu.pdf)

Malti (MT) (369.46 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/mt/documents/product-information/tecvayli-epar-product-information_mt.pdf)

Nederlands (NL) (328.43 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/nl/documents/product-information/tecvayli-epar-product-information_nl.pdf)

norsk (NO) (332.46 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/no/documents/product-information/tecvayli-epar-product-information_no.pdf)

polski (PL) (331.25 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/pl/documents/product-information/tecvayli-epar-product-information_pl.pdf)

português (PT) (314.8 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/pt/documents/product-information/tecvayli-epar-product-information_pt.pdf)

română (RO) (324.62 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/ro/documents/product-information/tecvayli-epar-product-information_ro.pdf)

slovenčina (SK) (314.86 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/sk/documents/product-information/tecvayli-epar-product-information_sk.pdf)

slovenščina (SL) (329.64 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/sl/documents/product-information/tecvayli-epar-product-information_sl.pdf)

Suomi (FI) (323.33 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/fi/documents/product-information/tecvayli-epar-product-information_fi.pdf)

svenska (SV) (312.72 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

08/10/2025

[View](/sv/documents/product-information/tecvayli-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254941 12/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tecvayli : EPAR - All authorised presentations

English (EN) (29.34 KB - PDF)

**First published:** 13/10/2022

[View](/en/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-670)

български (BG) (31.69 KB - PDF)

**First published:**

13/10/2022

[View](/bg/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.57 KB - PDF)

**First published:**

13/10/2022

[View](/es/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.13 KB - PDF)

**First published:**

13/10/2022

[View](/cs/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (31.65 KB - PDF)

**First published:**

13/10/2022

[View](/da/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (32.24 KB - PDF)

**First published:**

13/10/2022

[View](/de/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (28.56 KB - PDF)

**First published:**

13/10/2022

[View](/et/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (30.84 KB - PDF)

**First published:**

13/10/2022

[View](/el/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_el.pdf)

français (FR) (29.58 KB - PDF)

**First published:**

13/10/2022

[View](/fr/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.25 KB - PDF)

**First published:**

13/10/2022

[View](/hr/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (30.03 KB - PDF)

**First published:**

13/10/2022

[View](/is/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_is.pdf)

italiano (IT) (29.58 KB - PDF)

**First published:**

13/10/2022

[View](/it/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (30.16 KB - PDF)

**First published:**

13/10/2022

[View](/lv/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (29.88 KB - PDF)

**First published:**

13/10/2022

[View](/lt/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.59 KB - PDF)

**First published:**

13/10/2022

[View](/hu/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.65 KB - PDF)

**First published:**

13/10/2022

[View](/mt/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (30.08 KB - PDF)

**First published:**

13/10/2022

[View](/nl/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (30.94 KB - PDF)

**First published:**

13/10/2022

[View](/no/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.09 KB - PDF)

**First published:**

13/10/2022

[View](/pl/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.82 KB - PDF)

**First published:**

13/10/2022

[View](/pt/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_pt.pdf)

română (RO) (29.99 KB - PDF)

**First published:**

13/10/2022

[View](/ro/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.95 KB - PDF)

**First published:**

13/10/2022

[View](/sk/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.05 KB - PDF)

**First published:**

13/10/2022

[View](/sl/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.7 KB - PDF)

**First published:**

13/10/2022

[View](/fi/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (29.7 KB - PDF)

**First published:**

13/10/2022

[View](/sv/documents/all-authorised-presentations/tecvayli-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tecvayli Active substance teclistamab International non-proprietary name (INN) or common name teclistamab Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01F

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

## Authorisation details

EMA product number EMEA/H/C/005865

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Janssen-Cilag International N.V.

Turnhoutseweg 30

Opinion adopted 21/07/2022 Marketing authorisation issued 23/08/2022 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tecvayli : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (158.31 KB - PDF)

**First published:** 04/06/2025

**Last updated:** 08/10/2025

[View](/en/documents/procedural-steps-after/tecvayli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tecvayli : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (171.26 KB - PDF)

**First published:** 21/07/2023

**Last updated:** 21/10/2024

[View](/en/documents/procedural-steps-after/tecvayli-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tecvayli-H-C-PSUSA-00011010-202302 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/79368/2024

English (EN) (150.67 KB - PDF)

**First published:** 28/02/2024

[View](/en/documents/scientific-conclusion/tecvayli-h-c-psusa-00011010-202302-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tecvayli : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000083072

English (EN) (594.05 KB - PDF)

**First published:** 13/10/2022

[View](/en/documents/orphan-maintenance-report/tecvayli-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Tecvayli : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/789141/2022

English (EN) (6.65 MB - PDF)

**First published:** 13/10/2022

[View](/en/documents/assessment-report/tecvayli-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tecvayli

Adopted

Reference Number: EMA/CHMP/644929/2022

English (EN) (150.78 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tecvayli_en.pdf)

#### News on Tecvayli

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

[New medicine for multiple myeloma patients with limited treatment options](/en/news/new-medicine-multiple-myeloma-patients-limited-treatment-options) 22/07/2022

#### More information on Tecvayli

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-20-2331) on 19 October 2020. Product was withdrawn from the Union Register of orphan medicinal products by the European Commission in month &amp; year upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Tecvayli

- [Characterize infections and outcomes developed in relapsed/refractory multiple myeloma (RRMM) patients treated with Teclistamab (SPOT) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000414)

**This page was last updated on** 08/10/2025

## Share this page

[Back to top](#main-content)